...treat cancer. SciBX 3(25); doi:10.1038/scibx.2010.758 Published online June 24, 2010 Patent and licensing status undisclosed Carrington...

...Nanotherapeutics acquired DelSite's GelVac drug delivery assets in a Chapter 7 bankruptcy sale for $50,000. Nanotherapeutics...
...in a Chapter 7 bankruptcy sale for $50,000. Nanotherapeutics gains the GelSite delivery polymer and DelSite's...
...the deal will complement its drug delivery programs. DelSite filed for Chapter 7 in April. DelSite Inc....

...Carrington’s wound and skin care products under a 2000 deal (see BioCentury, Nov. 13, 2000). DelSite...
...start a Phase I trial of its H5N1 avian influenza nasal powder vaccine next quarter. DelSite Inc....

...Carrington’s DelSite Biotechnologies Inc. subsidiary extended a license to evaluate NIH’s polysaccharide technology’s ability to create...
...vaccine with DelSite’s GelSite delivery polymer. Terms were not disclosed (see BioCentury, May 21, 2007). Carrington...

...This year, Carrington’s DelSite Biotechnologies Inc. unit will begin a dose-escalation, U.S. Phase I trial in...
...DelSite Biotechnologies Inc. unit will begin a dose-escalation, U.S. Phase I trial in healthy volunteers. Carrington...

...In rabbit and rat models of bird flu, Carrington's avian H5N1 influenza vaccine was safe and...
...vaccine delivered using the GelVac nasal powder delivery system is expected to begin this year. Carrington...

...IRBO and CARN's DelSite Biotechnologies Inc. subsidiary will use DelSite's GelSite polysaccharide polymer to develop a...
...P, is in preclinical testing for multiple indications, including influenza. Financial details were not disclosed. Carrington...

...CARN's DelSite Biotechnologies Inc. subsidiary and ElSohly amended a 2007 deal to increase the number of...
...ElSohly amended a 2007 deal to increase the number of compounds ElSohly can combine with DelSite's...
...delivery technology. ElSohly is developing compounds to treat cancer and performs drug abuse testing services. Carrington...